<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005485</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#09-5287</org_study_id>
    <nct_id>NCT01005485</nct_id>
  </id_info>
  <brief_title>Molecular and Morphologic Characterization of Circulating Endothelial Cells</brief_title>
  <acronym>CEC</acronym>
  <official_title>Comprehensive Molecular and Morphologic Characterization of Circulating Endothelial Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis of this study is that circulating endothelial cells (CECs) harbor key&#xD;
      genetic and structural characteristics predisposing individuals to acute atherosclerotic&#xD;
      plaque rupture and heart attack.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial injury and inflammation are pivotal underlying processes that put patients at&#xD;
      risk for catastrophic vascular events including acute myocardial infarction (heart attack)&#xD;
      and stroke. We seek to accelerate scientific discovery through clinically meaningful,&#xD;
      innovative translational research, and are collaborating in a trans-disciplinary effort to&#xD;
      define the DNA sequence of CECs and that of germ line DNA, along with RNA sequencing, mRNA&#xD;
      expression profiling, and ultrastructural characterization of CECs in order to better&#xD;
      understand the mechanisms leading to acute arterial plaque rupture and embolization of&#xD;
      arterial endothelial cells in patients with acute myocardial infarction. This will enable us&#xD;
      to create a molecular fingerprint that could identify and preempt individuals from suffering&#xD;
      from such debilitating vascular conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is complete molecular profiling of CEC's in up to 250 patients with a diagnosis of acute myocardial infarction (MI) and up to 25 healthy controls.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">664</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Healthy controls will be recruited from the general medical population, community.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Myocardial Infarction</arm_group_label>
    <description>Patients with acute myocardial infarction with or without ST segment deviation.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for each patient will be collected from arterial access established as part of standard&#xD;
      of care or via venipuncture. Blood must be collected in the order listed below. By drawing&#xD;
      the PAX gene tube first, the likelihood of contamination of the sample with vessel wall&#xD;
      endothelial cells is decreased.&#xD;
&#xD;
      Enrollment:&#xD;
&#xD;
        1. x 8.5 ml PAX gene (blue top) tube&#xD;
&#xD;
        2. x 10 ml EDTA purple top tubes&#xD;
&#xD;
      Follow-up visits: (healthy controls only)&#xD;
&#xD;
        1. x 5 ml red top (discard)&#xD;
&#xD;
        2. x 10 ml EDTA purple top tube&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the general in-patient and out-patient populations for&#xD;
        myocardial infarction and/or vascular surgery. Healthy controls will be recruited from the&#xD;
        general medical population and community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - 80 years old.&#xD;
&#xD;
          2. Must be reliable, cooperative and willing to comply with all protocol-specified&#xD;
             procedures if consented.&#xD;
&#xD;
          3. Able to understand and grant informed consent&#xD;
&#xD;
          4. Subjects must meet one of the following (a-c):&#xD;
&#xD;
               1. Healthy control subjects not meeting any exclusion criteria for controls below&#xD;
&#xD;
               2. Patients scheduled for an open vascular procedure of an arterial structure&#xD;
&#xD;
               3. Patients with acute MI defined as:&#xD;
&#xD;
             i. Clinical history and symptoms consistent with acute MI AND ii Elevated cardiac&#xD;
             markers (CKMB, Troponin I or T) consistent with MI (abnormals are according to&#xD;
             enrolling institution's lab standards) AND iii. Able to complete study enrollment&#xD;
             (consent &amp; blood draw) within 48 hours of presentation to the study site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
        1. Has a significant medical condition that in the investigator's opinion may interfere&#xD;
        with the patient's optimal participation in the study.&#xD;
&#xD;
        Exclusion for Healthy Controls:&#xD;
&#xD;
          1. Age greater than 35&#xD;
&#xD;
          2. Previous history of coronary artery disease or MI&#xD;
&#xD;
          3. Diabetes&#xD;
&#xD;
          4. Peripheral arterial disease&#xD;
&#xD;
          5. Hypertension (&gt;140/90 or on blood pressure medication)&#xD;
&#xD;
          6. Sickle cell disease&#xD;
&#xD;
          7. Acute or Chronic kidney disease&#xD;
&#xD;
          8. Acute or Chronic vascular conditions, not otherwise specified&#xD;
&#xD;
          9. Active or history of inflammation of connective tissue and vascular structures (i.e.&#xD;
             vasculitis, rheumatoid arthritis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Topol, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scrippshealth</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2009</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Translational Science Institute</investigator_affiliation>
    <investigator_full_name>Eric Topol, MD</investigator_full_name>
    <investigator_title>Director, Scripps Translational Science Institute</investigator_title>
  </responsible_party>
  <keyword>Myocardial Infarction (MI)</keyword>
  <keyword>Circulating Endothelial Cells (CEC)</keyword>
  <keyword>Control Group A: (Vascular Surgery)</keyword>
  <keyword>Control Group B: (Healthy controls)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

